FindTrial
Sign In

Diagnostic utility of Aspergillus IgG, IgA, and IgM for chronic pulmonary aspergillosis: systematic review and meta-analysis

Diagnostic utility of Aspergillus IgG, IgA, and IgM for chronic pulmonary aspergillosis: systematic review and meta-analysis - Diagnostic utility of Aspergillus IgG, IgA, and IgM for chronic pulmonary aspergillosis: systematic review and meta-analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000039838
Enrollment
Unknown
Registered
2020-03-17
Start date
2020-03-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic pulmonary aspergillosis

Interventions

None listed

Sponsors

Department of Healthcare Epidemiology, Graduate School of Medicine and Public Health, Kyoto University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Pre-existing chronic pulmonary disease (cavitation, nodule/mass, pleural thickening, fibrosis, etc.) including regions caused by Aspergillus.

Exclusion criteria

Exclusion criteria: 1) Comorbid advanced cancer 2) Using prednisolone-equivalent systemic steroid treatment of more than 10 mg/day for >3 weeks 3) Using immunosuppressive drugs or biologics (e.g. TNF inhibitor, IL-6 inhibitor, anti-CD20 monoclonal antibody, methotrexate, etc.) within the past 90 days. 4) inherited severe immunodeficiency 5) acquired immunodeficiency syndrome (AIDS)

Design outcomes

Primary

MeasureTime frame
sensitivity and spedificity—

Countries

Japan

Contacts

Public ContactKeisuke Anan

Graduate School of Medicine and Public Health, Kyoto University Department of Healthcare Epidemiology

ekusiek_7@yahoo.co.jp075-753-4646

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026